DEF: Myriad Genetics Sets 2026 Annual Meeting Date, Proposes Director Elections

Myriad Genetics, Inc. announced its 2026 Annual Meeting of Stockholders, scheduled for June 4, 2026, to elect directors, ratify auditor selection, and approve executive compensation and equity plans.

Summary

• Myriad Genetics, Inc. is holding its 2026 Annual Meeting of Stockholders virtually on June 4, 2026, at 8:00 a.m. MDT.
• Key proposals include the election of three Class III Directors, ratification of Ernst & Young LLP as the independent auditor for 2026, advisory approval of executive compensation, and approval of amendments to the 2012 Employee Stock Purchase Plan and the 2026 Employee, Director and Consultant Equity Incentive Plan.
• The record date for voting is April 8, 2026.
• The company highlights its 2025 business performance, including a 1% increase in total test volumes, with hereditary cancer testing up 7% and mental health testing up 6%.
• Revenue for 2025 was $824.5 million, a 2% decrease year-over-year, but would have grown 2% excluding certain headwinds.
• Adjusted EBITDA for 2025 was $38.9 million, a decrease of $1.5 million from 2024.
• Adjusted EPS for 2025 was $0.06, down from $0.14 in 2024.
• The company is focusing its strategy on the Cancer Care Continuum, with plans to launch an AI-enhanced Prolaris test for prostate cancer and enter the Molecular Residual Disease (MRD) market with its Precise MRD platform in 2026.
• Significant leadership transitions occurred in 2025, with Samraat S. Raha appointed CEO, Brian J. Donnelly as Chief Commercial Officer, and Benjamin R. Wheeler as Chief Financial Officer.
• The company emphasizes its commitment to corporate responsibility, employee engagement (84% rated as a Great Place to Work), and sustainability initiatives.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing as cautiously optimistic. While the company is making strategic advancements and has strong employee and customer engagement metrics, the reported decline in revenue and significant GAAP net loss in 2025 indicate financial challenges that temper the overall sentiment.

Positives

• 84% of employees rated Myriad Genetics as a Great Place to Work in 2025.
• Healthcare provider Net Promoter Score (NPS) was 72.5 in 2025, considered excellent.
• Over 1.5 million molecular diagnostic and precision medicine test results were provided to patients and healthcare providers.
• Hereditary cancer testing volumes grew 7% year-over-year in 2025.
• Mental Health testing volumes grew 6% year-over-year in 2025.
• The company is expanding its oncology portfolio through collaborations with AI-enabled test developers.
• The company is entering the Molecular Residual Disease (MRD) market with its Precise MRD platform, targeting a $20 billion market.
• Eight out of nine directors are independent.
• 44% of Board members are women and/or ethnically diverse.
• The company has a strong governance framework with robust stock ownership guidelines and a clawback policy.

Negatives

• Revenue decreased by 2% to $824.5 million in 2025 compared to 2024.
• GAAP net loss was $365.9 million in 2025.
• Adjusted EBITDA decreased by $1.5 million to $38.9 million in 2025 compared to 2024.
• Adjusted EPS decreased by $0.08 to $0.06 in 2025 compared to 2024.
• The company experienced headwinds in 2025, including UnitedHealthcare's discontinuation of GeneSight coverage and the divestiture of its European EndoPredict business.

Risks

• Business results are subject to a variety of risks, including those described in the Form 10-K and other SEC filings.
• Forward-looking statements are not guarantees of performance and are subject to risks and uncertainties.
• The company's strategy relies on successful product launches and market adoption, which may not materialize.
• Competition in the molecular diagnostics and precision medicine markets is intense.

Future Outlook

The company expects annual revenue growth to accelerate to high-single-digit to low-double-digit percentages over the mid-to-long term, supported by planned investments in commercial capabilities for its expanded Cancer Care Continuum portfolio. The company plans to redirect and invest over $35 million over the next several years to expand commercial capabilities, support new product launches, and advance R&D programs while maintaining tight control over operating expenses.

Management Comments

• "Over the past year, we have made decisive progress in repositioning the company for accelerated, profitable growth by sharpening our strategic focus, strengthening our leadership team, and executing with greater urgency."
• "We enter 2026 as a more focused, disciplined, and confident organization - the New Myriad, prioritizing our resources, budget and attention where we have the greatest opportunity for delivering patient impact and right to win."
• "We believe 2026 will be an exciting, milestone rich year, with the launch of three significant diagnostic tests."
• "We are building on the foundational capabilities established in 2025 to accelerate profitable growth by focusing on the Cancer Care Continuum."
• "We are entering this new chapter with confidence in our strategy, our pipeline, our people, and our ability to execute."

Industry Context

StockSavvy.ai notes that Myriad Genetics' strategic focus on the Cancer Care Continuum, including expansion into Molecular Residual Disease (MRD) testing, aligns with broader industry trends towards personalized oncology and advanced diagnostics. The company's collaborations with AI-driven precision medicine companies also reflect the increasing integration of artificial intelligence in healthcare.

Comparison to Industry Standards

• Myriad's healthcare provider Net Promoter Score (NPS) of 72.5 is considered excellent, often exceeding industry benchmarks for patient and provider satisfaction.
• The company's employee engagement score, achieving the 84th percentile, indicates a strong internal culture compared to many companies in the life sciences sector.
• The executive compensation structure, with a significant portion of pay being variable and at-risk (81.8% for CEO, 74.4% for other NEOs), aligns with best practices in the industry for aligning executive interests with shareholder value.
• The company's peer group for compensation benchmarking includes companies like Exact Sciences Corporation, Guardant Health, Inc., and Veracyte, Inc., which are direct competitors in the molecular diagnostics and precision medicine space.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: The election of directors and approval of equity plans will impact corporate governance and future share dilution. Financial performance and future outlook will influence stock value.
• Employees: The proposed equity incentive plan and employee stock purchase plan amendment aim to provide incentives and opportunities for stock ownership, potentially increasing engagement and retention.
• Healthcare Providers and Patients: Continued focus on product development and market expansion in areas like cancer care and mental health aims to improve patient outcomes through advanced diagnostics.

Next Steps

• Elect three Class III Directors to the Board.
• Ratify the selection of Ernst & Young LLP as the independent registered public accounting firm for the year ending December 31, 2026.
• Approve, on an advisory basis, the compensation of named executive officers.
• Approve the proposed amendment to the Amended and Restated 2012 Employee Stock Purchase Plan.
• Approve the proposed 2026 Employee, Director and Consultant Equity Incentive Plan.
• Launch AI-enabled Prolaris test for prostate cancer in Q2 2026.
• Launch Precise MRD platform in 2026.
• Launch FirstGene, a multiple prenatal screen test, in the second half of 2026.

Key Dates

Recommendation

While Myriad Genetics is strategically positioning itself for future growth in key areas like cancer diagnostics and MRD testing, the recent financial performance shows a decline in revenue and profitability. The company's ability to execute its strategy and navigate market headwinds will be crucial. Given the mixed financial results and ongoing strategic execution, a 'hold' recommendation is appropriate, pending further evidence of sustained financial improvement and successful product launches.

Keywords

Myriad Genetics, Proxy Statement, Annual Meeting, Director Election, Executive Compensation, Equity Incentive Plan, Employee Stock Purchase Plan, Molecular Diagnostics, Precision Medicine, Cancer Care Continuum, Hereditary Cancer Testing, Mental Health Testing, Prenatal Health, Molecular Residual Disease, SEC Filing